Latest News

Bayhill's BHT-3034 receives FDA IND clearance for treatment of Myasthenia gravis

01/03/2011 10:00
Bayhill's Therapeutics novel BHT-3034 vaccine immunotherapy has been cleared by FDA for treatment of patients with myasthenia gravis. For further information see:

Rituximab Effective in Myasthenia Gravis

14/04/2010 10:00
A research group from Yale University have found promising evidence that the anti-CD20 antibody decreases B-cell activation, markedly reduces auto-antibody titers and improves symptoms in patients with myasthenia gravis (MG) unresponsive to current therapies. For more...

The case of Baby RB: Congenital Myasthenic Syndrome

10/11/2009 10:00
Baby RB, born with CMS meaning he could not breathe unaided, was allowed to die after his father withdrew his opposition to a high prolife court appeal. For more information...

New Treatment Boosts Muscle Function in MG

20/08/2007 10:00
A novel treatment produced by researchers at Hadassah Hebrew University Medical Center in Jerusalem, has been found to dramatically decrease the degree of muscle weakness in myasthenia gravis. EN101antisense is an anti-cholinesterase, which prevents the production...